Viloxazine in the treatmentof depressive neurosis

A controlled clinical study with doxepin and placebo

Joseph Patrick McEvoy, W. F. Sheridan, W. R.C. Stewart

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

In a four-week, double-blind, clinical trial thirty-one patients with depressive neurosis were treated with viloxazine, doxepin, or placebo. There were no differences among the three groups in therapeutic effects. Many depressed out-patients improve on placebo. Viloxazine hydrochloride is one of a series of compounds developed to explore the central nervous system activity of the aryloxypropranololamine type of β-adreno-receptor antagonists. Initial clinical studies support the hypothesis that viloxazine has antidepressant properties in man.

Original languageEnglish (US)
Pages (from-to)440-443
Number of pages4
JournalBritish Journal of Psychiatry
Volume137
Issue number5
DOIs
StatePublished - Jan 1 1980
Externally publishedYes

Fingerprint

Viloxazine
Doxepin
Depressive Disorder
Placebos
Therapeutic Uses
Antidepressive Agents
Outpatients
Central Nervous System
Clinical Trials
Clinical Studies

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Viloxazine in the treatmentof depressive neurosis : A controlled clinical study with doxepin and placebo. / McEvoy, Joseph Patrick; Sheridan, W. F.; Stewart, W. R.C.

In: British Journal of Psychiatry, Vol. 137, No. 5, 01.01.1980, p. 440-443.

Research output: Contribution to journalArticle

@article{ae12c5d1e6af41868ab30f258acd1a2b,
title = "Viloxazine in the treatmentof depressive neurosis: A controlled clinical study with doxepin and placebo",
abstract = "In a four-week, double-blind, clinical trial thirty-one patients with depressive neurosis were treated with viloxazine, doxepin, or placebo. There were no differences among the three groups in therapeutic effects. Many depressed out-patients improve on placebo. Viloxazine hydrochloride is one of a series of compounds developed to explore the central nervous system activity of the aryloxypropranololamine type of β-adreno-receptor antagonists. Initial clinical studies support the hypothesis that viloxazine has antidepressant properties in man.",
author = "McEvoy, {Joseph Patrick} and Sheridan, {W. F.} and Stewart, {W. R.C.}",
year = "1980",
month = "1",
day = "1",
doi = "10.1192/bjp.137.5.440",
language = "English (US)",
volume = "137",
pages = "440--443",
journal = "British Journal of Psychiatry",
issn = "0007-1250",
publisher = "Royal College of Psychiatrists",
number = "5",

}

TY - JOUR

T1 - Viloxazine in the treatmentof depressive neurosis

T2 - A controlled clinical study with doxepin and placebo

AU - McEvoy, Joseph Patrick

AU - Sheridan, W. F.

AU - Stewart, W. R.C.

PY - 1980/1/1

Y1 - 1980/1/1

N2 - In a four-week, double-blind, clinical trial thirty-one patients with depressive neurosis were treated with viloxazine, doxepin, or placebo. There were no differences among the three groups in therapeutic effects. Many depressed out-patients improve on placebo. Viloxazine hydrochloride is one of a series of compounds developed to explore the central nervous system activity of the aryloxypropranololamine type of β-adreno-receptor antagonists. Initial clinical studies support the hypothesis that viloxazine has antidepressant properties in man.

AB - In a four-week, double-blind, clinical trial thirty-one patients with depressive neurosis were treated with viloxazine, doxepin, or placebo. There were no differences among the three groups in therapeutic effects. Many depressed out-patients improve on placebo. Viloxazine hydrochloride is one of a series of compounds developed to explore the central nervous system activity of the aryloxypropranololamine type of β-adreno-receptor antagonists. Initial clinical studies support the hypothesis that viloxazine has antidepressant properties in man.

UR - http://www.scopus.com/inward/record.url?scp=0018911373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018911373&partnerID=8YFLogxK

U2 - 10.1192/bjp.137.5.440

DO - 10.1192/bjp.137.5.440

M3 - Article

VL - 137

SP - 440

EP - 443

JO - British Journal of Psychiatry

JF - British Journal of Psychiatry

SN - 0007-1250

IS - 5

ER -